Johnson & Johnson

Johnson & Johnson EBIT per Share

The EBIT per Share of Johnson & Johnson (JNJ) as of Oct 18, 2026 is 10.49 USD. In the previous year, EBIT per Share was 9.13 USD — a change of 15.00% (higher).

EBIT per Share

10.49USD

YoY

15.00%

Last updated:

EBIT per Share of Johnson & Johnson is 2025 10.49 USD. EBIT per Share of Johnson & Johnson was 2024 9.13 USD. It decreases by 15.00% higher compared to the previous year.

The Johnson & Johnson EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
8.99 USD
Jan 1, 2024
9.13 USD
Jan 1, 2025
10.49 USD
Jan 1, 2026 (e)
12.41 USD
Jan 1, 2027 (e)
13.67 USD
Jan 1, 2028 (e)
16.10 USD
Jan 1, 2029 (e)
17.96 USD
Jan 1, 2030 (e)
20.00 USD
The Johnson & Johnson EBIT per Share history
YEAREBIT per ShareYoY
est20.00USD+11.31%
est17.96USD+11.60%
est16.10USD+17.77%
est13.67USD+10.14%
est12.41USD+18.26%
10.49USD+15.00%
9.13USD+1.50%
8.99USD+13.97%
7.89USD+0.57%
7.84USD+6.09%
7.39USD-5.90%
7.86USD+1.07%
7.77USD+10.45%
7.04USD-6.86%
7.56USD+15.83%
6.52USD-12.18%
7.43USD+12.55%
6.60USD+9.81%
6.01USD+3.02%
5.83USD-1.88%
5.95USD-0.33%
5.97USD+3.29%
5.78USD+9.55%
5.27USD+13.06%
4.66USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Johnson & Johnson Stock analysis

What does Johnson & Johnson do? Johnson & Johnson is an American company that was founded in 1886 by the brothers Robert, James, and Edward Johnson. The company is headquartered in New Brunswick, New Jersey, USA and is now an internationally operating company with more than 130,000 employees worldwide. The history of Johnson & Johnson began with the production of medical bandages. In 1887, the first self-adhesive wound plaster was invented and patented. In the following years, the product range was significantly expanded and now includes a wide range of health products. This includes pharmaceuticals, medical devices, hygiene products, personal care products, and baby products. The business model of Johnson & Johnson is to improve the lives of people worldwide. The company places great importance on innovation, quality, and sustainability. With its long-standing experience and expertise in the healthcare industry, Johnson & Johnson is able to understand the needs of customers and offer products tailored to their specific needs. Johnson & Johnson is now active in three main business areas: Consumer Health, Medical Devices and Diagnostics, and Pharmaceuticals. Within these business areas, there are a variety of brands and products that are among the most well-known in the world. The Consumer Health division of Johnson & Johnson is focused on the production of health and personal care products for consumers. Some well-known brands in this area include Listerine, Johnson's Baby, Neutrogena, and Nicorette. The company offers a wide range of products, from cold and allergy medications to skincare products and toothpastes. Medical Devices and Diagnostics is another major business area of Johnson & Johnson. The company is a leading provider of medical devices and diagnostic products worldwide. Products in this area include surgical systems, implantable devices, diagnostic tests, and imaging devices. Well-known brands in this area include Ethicon, Depuy Synthes, and Cordis. Pharmaceuticals is the third major business area of Johnson & Johnson. The company develops and produces innovative pharmaceuticals for the treatment of diseases such as cancer, diabetes, heart disease, and neurological disorders. Some well-known brands in this area include Remicade, Invega, and Zytiga. Johnson & Johnson is also known for its commitment to sustainability and corporate social responsibility. The company is committed to having a positive impact on the environment and the communities in which it operates. For example, Johnson & Johnson aims to reduce its CO2 emissions by 60% by 2030. Overall, Johnson & Johnson is a leading healthcare company focused on providing innovative and high-quality products that improve the lives of people worldwide. With a wide range of brands and products in various business areas, the company is well positioned to continue to be successful in the future. Johnson & Johnson is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Johnson & Johnson stock

EBIT per Share of Johnson & Johnson is 10.49 USD in 2025.

EBIT per Share of Johnson & Johnson changed from 9.13 USD to 10.49 USD, representing a 15.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Johnson & Johnson since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Johnson & Johnson

All Key Metrics — Johnson & Johnson